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CVD is associated with vascular dysfunction and is often mediated by impainnents in nitric 
oxide (NO), a powerful vasodilator, and increased oxidative stress. Heat shock proteins (HSP), 
upregulate proteins linked to improving vascular functioning such as endothelial nitric oxide 
synthase (eNOS) and super oxide dismutase (SOD; an antioxidant). Therefore chronic passive heat 
therapy (CHT) may help improve cutaneous circulation in the microvasculature. PURPOSE: To 
investigate the in vivo effects of CHT on cutaneous NO-dependent dilation and to additionally 
elucidate the mechanisms behind the improvement through in vitro cell cultures. METHODS: 18 
subjects were immersed in 40°C water for 8wks, 4-Sx/week to maintain rectal temperature ~38.5°C 
for 60min. Prior to and following the last bout, two intradennal microdialysis fibers were inserted 
into the forearm and infused with lactated Ringer's solution (control) and L-NNA, to inhibit eNOS. 
Local skin heaters were placed at each site over the fiber and heated to 39°C at a rate of 0.1 C/sec, 
increasing skin blood flow, which was measured using laser-Doppler flowmetry. Data are presented 
as the change in NO-dependent dilation from Oto 8 weeks. Additionally post-heat therapy serum 
was collected at least 36h after the last session. Purchased human umbilical vein endothelial cells 
were cultured and exposed for 24h to either 37°C (control), direct heat at 39°C, or human sera 
collected at O and 8wks. eNOS, SOD, HSP70, and HSP90 protein expression was detennined using 
Western blot nonnalized to vinculin loading control. RESULTS: Subjects' NO-dependent dilation 
increased significantly (p=.0062). There were no improvements in sham subjects. Direct heating 
increased SOD expression in endoth~lial cells by 1.23±0.10 fold (p=0.045), HSP70 expression by 
1.32±0.03 fold (p<0.008), and HSP90 expression by 1.84±0.38 fold (p=0.04), but had no effect on 
eNOS (l.04±0.04 fold change, (F0.38). Serum exposure increased both eNOS (1.14±0.37 fold 
change, p<0.002) and SOD expression (l.29±0.09 fold change, p<0.01), with no change in HSP70 
(0.98±0.13 fold change, p=0.85) or HSP90 (0.94±0.08 fold change, p=0.51). Thus, CHT should be 
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The United States currently faces the massive threat of Cardiovascular Disease 
(CVD) accounting for over 30% of deaths nationally (7). This highly prevalent disease 
is typically characterized by vascular dysfunction. Vascular dysfunction is often caused 
by two major impairments in the vascular endothelium, defined as the inner lining of 
blood vessels. The first is a deficiency in nitric oxide (NO) bioavailability. NO is 
important for regulating the dilation or constriction in the blood vessels, the formation 
of new vessels, and preventing atherosclerosis. Therefore impaired measures of NO are 
highly correlated with cardiovascular risk and mortality (11). The second impairment is 
increased oxidative stress through the presence of free radicals. Free radicals have the 
ability to strip electrons from other molecules in an effort to become more stable. 
However the affected molecules are then made unstable and in turn will strip electrons 
from other molecules around them, thus resulting in a chain reaction that can cause 
catastrophic damage. One such affected molecule is NO, which can be bonded to the 
free radical superoxide to further exacerbate the vascular damage as ONOO-. 
However, there are means to combat these impairments. The physiological 
community has well established that exercise is one of the greatest preventative 
measures against CVD. Exercise helps to combat CVD by activating multiple signaling 
pathways that induce positive changes in both the vasculature and microvasculature.  
One of the primary reasons exercise is beneficial to cardiovascular health is 
because the energy that activates the working muscles is released as heat. The resulting 
rise in core temperature is then known to up-regulate heat shock proteins. These heat 






including those associated with improved NO bioavailability (13). Additionally it is 
known that exercise helps to reduce oxidative stress by restoring the balance between 
free radicals and antioxidants by upregulating proteins associated with improved 
antioxidant production. Antioxidants then reduce oxidative stress by donating an 
electron to the free radicals before they can continue to cause major damage to cellular 
membranes (2, 14). Superoxide dismutase (SOD) is one such antioxidant that can 
neutralize the negative effects of superoxide by binding to it. This ultimately allows for 
more NO bioavailability because fewer amounts of NO are being converted by free 
radicals into ONOO-. Therefore, both of these positive implications explain why 
exercise would be recommended for preventing chronic pathological cardiovascular 
conditions.  
However, in this assumption lies an inherent problem in that many patient 
populations are unable to fully engage or benefit from rigorous activity. Such 
populations can include but are not limited to spinal cord injury, diabetic, obese, or 
elderly patients. Many are limited from engaging in rigorous activity enough to induce 
major cardiovascular benefits. Therefore there becomes a desperate need for researchers 
to find alternative means for improving cardiovascular health for these patient groups.  
Animal studies have recently shown that chronic passive heat therapy (CHT) 
induces extensive cardiovascular benefits, many of which display a striking 
resemblance to those observed after chronic exercise training (5). For our purposes, 
repeated use of CHT is defined as the use of hot tub, sauna, or climate chamber heat to 
raise the internal core temperature of the subjects. However, while the chronic effects of 






the effects of chronic bouts of heat therapy (hot tub or sauna use) in humans over a long 
period of time.  
Therefore the purpose of this study is to determine if chronic passive heat 
therapy can induce positive cardiovascular benefits in human subjects over an 8-
week period of time by studying the effects of CHT on cutaneous NO 
bioavailability in the microvasculature. Furthermore, this study serves to elucidate 
the mechanisms behind the observed changes in human subjects.  
For this thesis we investigated how CHT impacts the molecular pathways 
involved with NO signaling. This was done first through in vivo studies using the intact 
cutaneous microcirculation in the forearm. In vivo is defined as a study that is 
performed in a living organism, in this case humans. Studying the changes induced on 
the microvasculature is a strategic method of gauging overall cardiovascular health. 
This method is effective because pathologies will typically surface in the 
microvasculature first before presenting itself in the greater circulatory system (7). By 
studying changes in the microvasculature we can deduce what would likewise be 
occurring in the major vascular system. Furthermore, impairments in the 
microvasculature can prove to be detrimental to the body as it primarily serves to the 
deliver nutrients such as oxygen as well as uptake carbon dioxide from the tissues. The 
microcirculation also assists with regulating blood flow and maintaining blood pressure 
throughout the body. Therefore damages to the microvasculature cannot only indicate 
future impairments in the macrocirculation, but it can also be catastrophic in itself. 
Additionally an in vitro component has been included for this study. In vitro is 






particular study, cultured human umbilical vein endothelial cells (HUVECs) were used 
to elucidate the mechanisms behind the observed improvement in the microvasculature. 
In practice, cultured endothelial cells would be exposed to simulated conditions that the 
human subjects’ cells would experience. By simulating the conditions that subjects’ 
endothelial cells were exposed to in a controlled laboratory setting, we would be able to 
reveal the signaling cellular pathways that account for the adapted NO bioavailability. 
Such a study is important for acutely understanding how passive heat therapy can be 
used to induce cardiovascular benefits. 
Therefore, by combining both an in vivo as well as in vitro component for this 
study, we can simultaneously understand how chronic passive heat therapy can be used 
as a beneficial method of improving cardiovascular health, as well as the mechanisms in 
which it does so. The reasoning behind these methods are that cultured endothelial cells 
allow us to see the mechanisms behind the increased NO that cannot be otherwise 
observed in humans. Such understanding could potentially be used for the direction of 











Multiple studies by Dr. Horowitz have highlighted the improvements in 
cardiovascular health post heat acclimation in animal studies. In one such study 
Horowitz observed that heat acclimation increased the bioavailability of HSP70. 
Additionally they found that heat acclimation resulted in improved protective effects 
that could delay thermal injury by preventing cell death. Therefore, if such results can 
be concluded by animal studies, the next step would be to study the effects of CHT in 
humans and observe whether or not these results are replicable (5). 
A study by Akasaki et al. also studied rats to determine the effects of heat 
therapy through repeated infrared dry sauna exposure. The heat therapy mice were 
placed in the saunas 41 for 15 minutes and then at 34 for 20 minutes daily for 5 weeks. 
Using Laser Doppler imaging, which will be described in the Microdialysis Skin Study 
section, they observed the effects of heat therapy on perfusion. They also found that 
capillary density had significantly increased in the heat therapy group. Lastly, they also 
studied the effects of heat therapy on endothelial nitric oxide synthase (eNOS) 
expression. This was done in order to see if the protein was possibly involved in the 
heat therapy induced angiogenesis. They concluded that the angiogenesis that the 
greater capillary density could in fact be attributed to eNOS which was upregulated by 
the heat therapy protocol. (1) 
Among the very limited research conducted in humans that examined the effects 






this study sought to understand the association between sauna bathing and fatal 
cardiovascular events (heart attacks) over an extended period of time. Around 2,600 
men aged 42 to 60 were given baseline examinations between the years of 1984 and 
1989 to evaluate their frequency of sauna bathing. In the years after, checking hospital 
documents and death certificates followed up all deaths. There were no losses to follow-
up (8). They found that subjects who engaged in sauna bathing experienced a lower risk 
of CVD and coronary heart disease. For subjects practicing 2-3 sauna sessions per 
week, their risk of a fatal coronary heart disease event was 23% lower. Furthermore, 
subjects who practiced 4-7 sauna baths per week experienced 48% lower risk. All of the 
findings for this study were significant (8). 
However multiple barriers must be overcome when studying CHT for the 
purpose of being a potential method of improving cardiovascular health in patient 
populations. One such barrier is the fear that hot tubs are unsafe for patient populations. 
Tei et al. therefore conducted a study evaluating the responses to warm-water and sauna 
baths in 34 subjects already experiencing chronic heart failure. Subjects were immersed 
in either 41°C water to the sub-clavicular level for 10 minutes or an infrared-ray sauna 
for 15 minutes depending on the study day. Measurements of subjects’ hemodynamic 
changes were monitored before, during, and for 30 minutes after the study. They found 
that none of the subjects experienced dyspnea (labored breathing), angina pectoris 
(chest pain due to lack of oxygen supplied to the heart), or arrhythmia (abnormal heart 
rhythm) during any of the 68 trials. Alternatively they found that cardiovascular 






failure. This shows that when monitored, using hot tubs cannot only be a safe practice 
in patient populations but also incredibly beneficial (15). 
Microdialysis Skin Study  
Cutaneous hyperemia, or rapid local skin heating has been widely used by 
researchers to assess microvascular function (12). Dilation in these vessels are highly 
dependent on NO (NO-dependent dilation). Furthermore because NO-dependent 
dilation can become impaired under a variety of disease conditions, it is considered a 
representative of globalized microvascular functioning (4,5).  
During cutaneous hyperemia, multiple factors contribute to the general local 
heating response. Therefore, Choi et al. sought to differentiate the CVC responses 
dependent upon endothelial-derived hyperpolarizing factors versus NO-dependent 
dilation. By comparing nine heating protocols they were able to establish that locally 
heating the skin to 39°C was the best approach for isolating NO-dependent dilation (4). 
This approach was therefore used for the purposes of this study.  
Laser Doppler flowmetry is a technique that can be used to determine the 
cutaneous blood flow through the microvasculature. Combined with the mean arterial 
pressure, cutaneous vascular conductance (CVC) can be calculated in order to evaluate 
microvascular functioning. The microvasculature will be used for this study because of 
its easily accessible location. Furthermore, the microvasculature is representative of 
overall cardiovascular functioning (4,11). 
Microdialysis fibers can be used for the infusion of drugs in order to determine 
the response by a local capillary bed during the local heating response. The semi-






various experimental conditions. The laser in the Laser-Doppler flow meter unit can 
then be used to measure the blood flow through that capillary bed after the drug 
response. Laser Dopplers work by projecting a light source into a tissue, the distribution 
of that light can then be used to estimate blood flow.  
Local heating typically results in three characteristic responses (11). 
Immediately after heating, the skin’s CVC will increase up to a peak value. This peak 
will not be evaluated for this study, as it is typically characteristic of an axonal reflex 
rather than NO dependent. The second response is a nadir. This portion of the response 
occurs when the axonal response is simultaneously receding while the NO-dependent 
dilation is increasing. The last part of the response is the plateau, which is almost 
entirely NO dependent. 
  
Figure 1: Typical response to local heating 
L-NNA is a drug that can be used to wipe out the NO response to local heating. 
In pilot data it was determined that 10mM was the lowest dosage given that could 
induce a maximal local heating response. This is accomplished by non-specifically 






NNA, any increase in CVC that would have been attributed to NO is hereby blocked. 
Therefore by comparing an L-NNA site to a controlled local heating plateau, all CVC 
between those two measures can be attributed to NO, defined as NO-dependent dilation.  
 
Cellular Study 
Cellular cultures employing human cells can be used to easily deduce what is 
likely occurring in the human body without the need of biopsies or other invasive 
procedures. This study utilized purchased human umbilical vein endothelial cells 
(HUVECs). The HUVECs will be grown and cultured in the lab before being exposed 
to the experimental conditions. 
For the purposes of this study, HUVECs will be exposed to direct heating and 
serum from heat acclimated subjects. This is in an effort to simulate the effects of heat 
therapy in cultured cells to what was likely experienced in vivo by the endothelial cells.  
In this study we will be observing four specific proteins: Endothelial nitric oxide 
synthase (eNOS), which breaks down L-arginine to form L-citruline and NO as a 
byproduct. Superoxide dismutase (SOD), an antioxidant. Heat shock protein 90 
(HSP90), which stabilizes eNOS. Lastly, heat shock protein 70 (HSP70), which 
upregulates the production of SOD.  
Western blots are a widely accepted method of evaluating protein expression 
after cells are exposed to experimental conditions. Mahmood et al. explains that by 
utilizing this technique, researchers will be able to identify specific proteins in the cells. 
Using gel electrophoresis, proteins are separated based on molecular weight. A band for 






antibodies. The thickness/darkness of the band thus indicates the amount of protein 
present. (10) Western Blots for this study will be used to study the changes in protein 










For this study we recruited 76 subjects. Of those 76 subjects assessed for 
eligibility, 27 were randomized into either the heat therapy group (n=13) or the sham 
group (n=14). Of those subjects (n=8) of the heat therapy subjects or (n=10) of the sham 
subjects were analyzed. All subjects were young (18-30 yrs), healthy, but otherwise 
sedentary. Sedentary is defined as engaging in less than 2 hours of cardiovascular 
exercise per week. All subjects were pre-screened prior to the engagement in any 
protocol. This study screened for cardiovascular diseases in the subjects’ family 
histories. Additionally all subjects on prescription medications, with the exception of 
oral birth control, were excluded from this study. During the pre-screen all subjects 
were made aware of the protocols the study required. All subjects were told that they 
could leave the study at any time and would be compensated for the time they had 
participated. Lastly, signatures of informed consent were gathered as prescribed by the 
Declaration of Helsinki. Institutional Review Board approval was acquired for all 
protocols pertaining to this study (See Appendix A). 
Heat Therapy 
Procedure 
Prior to coming to the lab, all subjects were asked to collect a urine sample after 
waking and before drinking any fluids/consuming food. This standard was set to ensure 
that the sample would be a credible representation of the subjects overall hydration. 






at ≤1.02. All subjects falling above this standard were asked to consume 5ml/kg of their 
body weight. Nude body weight was obtained prior to rectal probe instrumentation. 
After recording body weight, subjects instrumented themselves with a rectal probe (YSI 
Series 400; Yellow Spring Instruments, Yellow Springs, OH) that was inserted ~10cm 
beyond the anal sphincter.  
Subjects were then immersed in 40.5°C hot tub. All subjects were asked to sit 
with the water level up to their clavicles in order to drive rectal temperature up to 
38.5°C. Once the target rectal temperature of 38.5°C was reached, subjects were 
allowed to sit up with the water level at their waist. This target temperature was chosen 
because it is considered the threshold for heat shock protein activation. 
 Subjects stayed in the hot tub for an hour after the target temperature was 
reached or until 90 min total of immersion, whichever came first. Subjects were then 
asked to sit out of the tub for 10 minutes post immersion until rectal temperature fell 
below 38.5°C. 
Throughout the entire immersion and for the 10 minutes following, rectal 
temperature, heart rate, water temperature, subject position, and general notes were 
recorded every 5 minutes. This was done in order to ensure that the subject stayed 
within safe levels of internal temperature. Additionally the weight of fluids consumed 
during the immersion was also recorded.  
At the conclusion of the 10 minutes post immersion, subjects’ nude body weight 
was again recorded. Using the pre and post weights, as well as factoring out fluids 
consumed, sweat loss was calculated. If a subjects’ post body weight was >1% pre body 






body weight loss. This was to ensure that subjects were euhydrated at the conclusion of 
the study for their own safety.  
This protocol was repeated for each subject 4-5 times/week for 8 weeks, a total 
of 36 hot tub sessions. Protocol was repeated in sham subjects with the exception of the 
tubs being filled with 36.5°C water and rectal temperature was not driven up to 38.5°C. 
Rather, rectal temperature was maintained at baseline levels throughout the immersion. 
Microdialysis Skin Study 
 
Figure 2: Skin study protocol 
Procedure 
Prior to the first hot tub session and 36-72 hours after the last session, a skin 
study was conducted. Female subjects were asked to provide a urine sample beforehand 
to rule out pregnancy. Additionally all subjects were screened to be sure that the 
subjects had no food (4hrs), caffeine or alcohol (>12hrs), 
medications/vitamins/supplements (24hrs), and exercise (24hrs) before the planned 
study day. Height and weight were also recorded. 
Subjects were told to sit in a semi-recumbent chair while resting their left arm 
on a table. On the ventral forearm 2 skin sites for fiber placement were then located 
≥4cm apart from each other. Care was taken to avoid veins, hair, or sun damaged areas 






needle was embedded 1-2mm under the skin and exited ~25 mm away. A microdialysis 
fiber (MD2000, 30-kDa cutoff membrane; Bioanalytical Systems, Inc., West Lafeyette, 
IN, http://www.basinc.com/products/iv/probes_linear.php or CMA 31 Linear Probe, 55-
kDa cutoff membrane; CMA Microdialysis AB, Kista, 
Sweden, http://www.microdialysis.com/us/products/probes/cma-31-linear), which is a 
permeable fiber that can infuse intended drugs, was then threaded through the needle. 
Once in place, the needle was removed leaving the permeable fiber in place under the 
skin. This procedure was repeated for the second site. 
Lactated Ringers, a solution comparable to saline (salt water), was infused 
through the fastened fibers. Infusion proceeded at a rate of 2µL/minute. A check was 
done to ensure that the fibers were perfusing properly throughout the duration of the 
study. 
Drugs were mixed while the subject rested in place for 1 hour in order for the 
inflammation in the forearm to recede. During this time the subject was instrumented 
with a blood pressure cuff on the left arm (CardioCap; Datex-Ohmeda, Louisville, CO). 
An initial blood pressure and heart rate was recorded in addition to one after 20 minutes 
of rest. Blood pressure was taken every 5 minutes. 
During the last 15 minutes of rest, local heaters (SH02 Skin Heater/Temperature 
Monitor; Moor Instruments, Axminster, UK) and Laser-Doppler probes (MoorLab; 
Moor Instruments) were placed over the two fiber sites in addition to one control site. 
Once sure that the inflammation had passed and stable values were recorded, all local 
heaters increased temperature to 33°C. This temperature was chosen in order to control 






conditions. Pre-drug baseline was then recorded for 5 minutes. Additionally BP and HR 
were recorded. 
After pre-drug baseline, the Lactated Ringers syringes were replaced with 
Lactated Ringers at Site 1 and L-NNA at Site 2. Site 3 was left as a control. All sites 
were determined randomly.  
After post-drug baseline, all local heaters increased temperature to 39°C at a rate 
of 0.1/second. Skin blood flow was recorded throughout this process until all sites hit a 
stable plateau for at least 5 minutes. 
Lastly the local temperatures of the heaters were increased to 43.5°C at a rate of 
0.1/second. Additionally, all syringes were replaced with 56mM sodium nitroprusside 
(SNP) and perfused through the fibers. This is a substance that can be used to lower 
blood pressure and induce vasodilatation. These two methods were used in combination 
to ensure that all sites displayed maximal blood flow. The study concluded when a 
plateau was reached in the observed skin blood flow.  
Statistical Analysis 
Baseline, initial peak, nadir, and plateau cutaneous vascular conductance in the 
Ringer's site were compared using two-way RM ANOVA with factors of phase during 
local heating and weeks into chronic heat therapy (0wks vs. 8wks). The values for CVC 
were calculated by dividing the observed Laser-Doppler flux values by the mean arterial 
pressure acquired by the blood pressure cuff. All CVC values were then normalized as a 
percentage of maximal CVC. Pairwise comparisons of the %CVC max were then made 






across weeks into heat therapy using Student's paired t-test significance was set to 
P*<0.05. 
 Drug Mixing 
Drugs were mixed during the subject’s initial hour of rest. Two drugs were 
mixed for the local heating portion of the study. For the first 10ml syringe, labeled 
10mM L-NNA, 0.0110g L-NNA was weighed out in a clean beaker. 5ml Ringers was 
then added in addition to a small stir bar. The solution was stirred at a high speed at low 
heat until completely dissolved (20min). Solution was then pulled up into the 10ml 
syringe labeled 10mM L-NNA.  
For the max CVC portion of the study 0.0167g SNP was weighed out into a 
clean beaker. 1ml of Ringers then added and whirled until fully dissolved before being 
pulled back up into a 3ml syringe. Drugs were filtered through a 5μm filter before being 
transferred to fill three 1ml syringes with 56mM SNP. All syringes containing SNP 








Figure 3: Cellular study protocol 
Procedure  
Venous blood was drawn prior to the first hot tub bout (0wks) and 24-48 hours 
following the last immersion (8wks). As a control, all subjects were fasted for 4 hours 
and had abstained from any caffeine or alcohol 12 hours prior to the draw. Additionally 
subjects were asked to refrain from any medications or exercise 24 hours prior to the 
study. Samples were drawn into serum separating vacutainers and then separated by 
centrifugation. All blood samples were stored using standardized preservation protocols 
at -80°C for later use.  
Human umbilical vein endothelial cells (HUVECs) were grown and cultured 
using standardized procedures, and were used in experiments after 2-3 passages and 
following a 4h serum starve. All HUVECs were then plated and exposed to 1 of 4 
conditions. For the direct heating portion of the study, cells were incubated at either 






protocol). Cells were then kept in either of these two conditions for 24 hours and then 
collected for further analysis.  
For the serum exposure portion of the study, cells were exposed to 10% serum 
(100μl in 1ml of culture medium), which had been collected at either 0wks (control) or 
8wks (heat acclimated). Once again cells were incubated in these conditions for 24 
hours at 37°C and then collected. 
Western Blotting 
Using electrophoresis on 4-20% SDS polyacrylamide separating gels (Life 
Technologies, Grand Island, NY), 20-50μg of protein were transferred onto 
nitrocellulose membranes (Bio-Rad, Hercules, CA). Ponceau was used to stain the 
membranes before they were incubated for 1 hour in Odyssey Blocking Buffer (LI-COR 
Biosciences, Lincoln, NE). This was done in order to verify that the proteins were 
transferred onto the membrane successfully. The membranes were then further 
incubated overnight at 4°C. During this time the membranes were set in blocking buffer 
that contained primary antibodies (listed below). The next day the membranes were 
washed and incubated with their respective secondary antibodies (LI-COR 
Biosciences). This was conducted for 1 hour at room temperature. The bands shown on 
the membrane were analyzed using LI-COR Odyssey infrared imaging system (LI-COR 
Biosciences) in order to be quantified using LI-COR Image StudioTM software.  
Primary antibodies for HUVECs were: 1) anti-endothelial NO synthase (eNOS) 
(1:1,000; Cell Signaling Technology, Danvers, MA) 2) anti-superoxide dismutase-






Abcam, Cambridge, MA) 4) anti-Hsp70 [BRM-22] (1:5,000; Abcam), and 5) anti-
vinculin (loading control; 1:1,000; Cell Signaling Technology). 
Statistical Analysis 
Results were acquired from the Western Blots relative to the vinculin loading 
control (a method of establishing consistencies among samples). Changes in protein 
expression of eNOS, SOD, HSP70 and HSP90 were then compared using a Student’s 
paired t-test for the serum exposure and an un-paired t-test for the direct heating results. 











Microdialysis Skin Study 
  
Figure 4: Effects of heat therapy on local heating response 
Heat therapy significantly increased the peak value and plateau during the local heating 
response (p<0.0001 and p=-.012 respectively). No significant change found in sham 
subjects’ peak (p=.099) and plateau (p=0.22). 
 
 
Figure 5: Effects of heath therapy and sham conditions on NO-dependent dilation 
Heat therapy significantly improved mean value of NO-dependent dilation (p=0.0062), 






Heat therapy adjusted the local heating response by significantly increasing both 
the initial peak and plateau values (p<0.0001 and p<0.01 respectively). Even though the 
initial peak is not entirely NO dependent, there was still a significant difference between 
the control and the L-NNA site. This indicates that there must have been some change 
in NO bioavailability.  The plateau site supports this conclusion because the significant 
change between 0 and 8 weeks indicates that there was a dramatic change in NO 
bioavailability in the microvasculature. This can be inferred because much of the 
plateau response occurs due to NO-dependent dilation. Important to note, NO-
dependent dilation increased in all subjects. Conversely no significant change in local 
heating response was observed in in the sham subjects. 
This justification is further supported by the significant increase in NO-
dependent dilation (p=0.0062), reported as a percentage of maximal CVC. Sham 















Cellular Study: Serum Exposure 
 
Figure 6: Effects of serum exposure on protein expression 
Serum exposure significantly increased eNOS expression 
by 1.14±0.37 fold change, p<0.002, and SOD expression 
by 1.29±0.09 fold change, p<0.01. Serum exposure had no 
effect on HSP90 (0.94±0.08 fold change, p=0.51) and 







Cellular Study: Serum Exposure Continued 
After cells were exposed to 24 hours of exposure to heat acclimated serum, there 
was a significant increase in eNOS protein expression (p<0.002). Additionally we 
observed a significant increase in SOD expression after the exposure (p<0.01). 
Conversely neither HSP90, nor HSP70 expression were increased after the exposure to 
serum (p=0.51 and p=0.85 respectively). These results can be observed in the example 
blots from cultures using subject 8 and subject 9’s zero and eight-week serum. An 
increased darkness or thickness of the band indicates increased protein expression. Such 
results indicate that eNOS and SOD can be upregulated through mechanisms 
independent of intracellular effects of direct heat. Therefore there must be other 







Cellular Study: Direct Heat Exposure 
 
Figure 7: Effects of direct heat on protein expression 
Exposure to direct heat significantly increased SOD by 
1.23±0.10 fold (p=0.045), HSP90 by 1.84±0.38 fold 
(p=0.04), and HSP70 by1.32±0.03 fold (p<0.008) .eNOS 







Cellular Study: Direct Heat Exposure Continued 
HUVEC exposure to direct heating resulted in a significant increase in SOD 
expression (p=0.045), but no significant change was found in eNOS protein expression 
(p=0.38). Furthermore, in contrast to the serum exposure, direct heating resulted in 
significant increases in both HSP90 and HSP70 (p=0.04 and p<0.008 respectively). The 
blot examples display the contrast in band thickness for four samples that either 
exposed to heating at 37°C or 39°C. These results indicate that passive heat can induce 
an upregulation of SOD, HSP70, and HSP90 through mechanisms mediated by direct 







The purpose of this study was two-fold. The first component was to observe the 
effects of long-term exposure of bouts of heat on NO bioavailability in the 
microvasculature. To the best of our knowledge this is the first study to observe the 
mechanisms behind the effects of CHT in the microvasculature. Our primary finding 
was that following the 8-week passive heat protocol, the local heating response in the 
microvasculature significantly improved. This was largely due to the increased amounts 
of NO in the microvasculature, indicated by the significant increase in the plateau 
response at the control site with no difference in the L-NNA site.  
Consistent with what was mentioned previously, a change in the difference 
between the L-NNA response and the Ringer’s/control site’s plateau is indicative of a 
change in NO bioavailability. As seen in Figure 4, the difference between the two 
responses significantly increased after the 8-week therapy. This improvement therefore 
likely indicates that there must be greater amounts of NO in the microvasculature that 
are allowing the vessels to dilate. Additionally it means that the NO present is actually 
functioning to dilate those vessels. It is significant to note that the improvements were 
found in all the heat therapy subjects.  
When there is a rise in core temperature and therefore an increase in blood flow 
to the skin, we can suspect that such improvements can be attributed to two factors. The 
first is that this dissipation leads to the increase in shear stress, a mechanical force 
caused by increased blood flow through the vessels, which in turn is largely responsible 
for the acute change in diameter of the vessel. Shear stress is known to induce many 






eNOS (16). An upregulation of eNOS expression therefore results a greater amount of 
NO production in the vessels (1). The second factor is the resultant increased 
temperature in the skin due to the blood flow. This increase in skin temperature can lead 
to the activation of heat shock proteins that are associated with increased NO 
bioavailability. 
However, we could not have known for certain the pathways of the improved 
bioavailability without the second component of this study. Therefore the second 
purpose was to elucidate the mechanisms behind the observed improvements using 
cellular cultures in simulated and controlled environments. 
Exposure to serum from subjects after the 8-week protocol was shown to 
significantly improve both eNOS and SOD expression. However, both heat shock 
proteins 70 and 90 did not improve. Such findings indicate that there must be unknown 
circulating factors in the blood samples that were upregulated after heat therapy. In turn 
these upregulated factors induced an increased amount of eNOS and SOD, independent 
of heat shock protein mediated intracellular effects. 
Conversely, direct heating significantly improved the expression of SOD, 
HSP70 and HSP90 while eNOS expression remained unchanged. This indicates that the 
three former proteins can all be upregulated by heat induced intracellular effects. This 
makes sense when considering that heat is well known to upregulate heat shock proteins 
(13). However it also notably shows that eNOS is not upregulated directly by heat but 
by other factors in the blood that have been upregulated by long-term heat exposure.  
These results indicate that it is the rise in internal temperature that upregulated 






consistent with what is seen in exercising populations. It is likely the increase in HSP70 
from the direct heating that upregulated the production of SOD (13,14). These 
improvements are important because the increased amount of antioxidants can therefore 
combat oxidative stress by neutralizing superoxide in the blood stream. This 
neutralization of free radicals allows for the NO produced to continue to function 
properly. Furthermore, while there may not have been an increase in expression of 
eNOS from direct heating, the dramatic increase in its co-factor HSP90 is likely one of 
the reasons that allowed for the increase in NO production. This is because more HSP90 
was available to be a cofactor for eNOS, which is necessary for the production of NO. 
The eNOS protein was unique from the other studied proteins in that it was not 
upregulated by direct heating, but rather solely from the exposure to the subjects’ 
serum. This means that there was another factor we were unaware of in the subjects’ 
blood that was upregulated by the heat therapy. Having increased circulation to the skin 
allowed for the circulating factors to upregulate the expression of eNOS. The elucidated 







Figure 8: Working model of NO signaling pathway 
Lastly, no improvement in the sham subjects was observed after the 8-weeks of 
thermoneutral water immersion. A sham group was used for this study rather than a 
time control group in order to rule out the possibility that it is the immersion in water 
that induced the observed results. Because only the hot water immersion resulted in 
improved NO-bioavailability, it can be concluded that it was the passive exposure to 
heat that induced the positive changes in the microvasculature.  
Such findings indicate that chronic passive heat therapy is an effective way of 
improving cardiovascular functioning in the microvasculature. On a larger scale these 
results suggest that CHT can induce positive physiological responses in the greater 
cardiovascular system. By having upregulated amounts of HSPs, eNOS, and 
antioxidants such as SOD, both impaired dilation and oxidative stress, factors that can 








There were a few limitations to this study. All of the subjects were young and 
healthy. Therefore further studies must be conducted before we can fully claim that heat 
therapy through hot tubs can improve cardiovascular health in patient populations. 
However, we chose to study the sedentary population because we questioned whether or 
not CHT could make healthy subjects even healthier. Other exercise studies have used 
the sedentary populations with similar goals and intentions. 
Additionally we used the cutaneous microvasculature in the forearm to make 
claims about global microvascular health (7).  However, in order to reasonably adjust 
for this limitation, we had the subjects always sit in the hot tub with their study arm out 
of the water. By doing so, we concluded that any changes in the microvasculature 


















In conclusion, our study suggests that exposure to chronic passive heat therapy 
will result in greater amounts of NO bioavailability. NO will then in turn help with 
reducing the amount of stress on the cardiovascular system by acting as a powerful 
vasodilator and improving overall vascular function. 
The in vitro component of this study elucidated the mechanisms behind the 
improvements in NO bioavailability. Both the effects of circulating factors and 
intracellular effects of heat either directly or indirectly allowed for increased production 
and usage of NO. These results likely underlie the observed improvements found in 
vascular function during the skin portion of the studies.  
Future studies may benefit from investigating the effects of passive heat therapy 
in spinal cord injury, diabetic, or obese patient populations. Additionally on the cellular 
component, adding an assay to evaluate whether or not there was an increase in eNOS 
functionality could be beneficial for cementing the reason for the improvements in NO-
dependent dilation. 
Therefore it can be concluded that chronic exposure to passive heat, should be 
further investigated as a means of improving cardiovascular health in patient 
populations. Perhaps hot tub or sauna use can become a clinical alternative for lowering 










Appendix A: Informed Consent Documents 
 
Group 1: Able-bodied Heat Therapy 
TITLE: “Chronic heat exposure and cardiovascular health”   
INVESTIGATORS: Vienna E Brunt, M.S., Dr. Christopher T Minson, and colleagues 
APPROVED BY INSTITUTIONAL REVIEW BOARD:  February 5, 2014 
This is an important form.  Please read it carefully.  It tells you what you need to know 
about this study.  If you agree to take part in this research study, you need to sign this 
form.  Your signature means that you have been told about the study and what the risks 
are.  Your signature on this form also means that you want to take part in this study. 
Why is this study being done? 
Cardiovascular disease is the number one cause of death in the United States. 
Exercise is a potent means of improving cardiovascular health, but not all patient 
populations are able to exercise effectively. There is high demand for novel 
therapies to better manage cardiovascular risk in these patients. Heat exposure 
can have many beneficial effects on the cardiovascular system. As such, long-term 
heat exposure (i.e. sitting in a hot tub 4-5x per week) may provide an alternative 
means to exercise for improving cardiovascular health. This project will assess the 
benefits of long-term heat exposure on the health of the vasculature and on the 
cellular pathways that improve vascular health, which is important as the majority 
of cardiovascular diseases affect the arteries. We will measure various biomarkers 
of vascular health before and after 8 weeks of heat exposure in able-bodied 
individuals and patients with spinal cord injury. SCI patients are a population with 
elevated cardiovascular risk who have limited exercise capabilities, and who may 
be able to utilize chronic heat exposure as an alternative to exercise training for 
improving cardiovascular health. Additionally, prehypertensives represent 
another patient population with elevated cardiovascular risk whose 








We will address the following questions in this study:   
• How does 8 weeks of passive heat exposure affect cardiovascular health, as 
measured by various biomarkers of cardiovascular function? 
• How does 8 weeks of passive heat exposure affect levels of factors circulating 
in the blood and located within muscle tissue that are important for 
cardiovascular health? 
• Do effects differ between healthy normotensive able-bodied individuals and 
spinal cord injury patients? 
What will happen in the study? 
1. If you are interested in participating in the study, we will schedule an 
appointment with you to meet with one of the investigators of the study to 
discuss the project, to see the laboratory, and to read this form. If we have 
scheduled this appointment, it means you meet all initial subject criteria (based 
on initial phone and/or email conversations).  
2. Additionally during this initial session, you will fill out a health history form 
and may meet with a physician, so that we can ensure you are healthy enough 
to participate in the study. In addition, the physician will be available to you to 
answer any medical questions or concerns you may have throughout the 
duration of your participation in the study. This visit should last about 60 
minutes.  
3. We will assign you to a subject group. If you are reading this form, you are in 
the able-bodied heating group.  
4. Throughout the study, you will report to the laboratory 4-5 times per week for 
8 weeks for hot tub sessions. Additionally, you will participate in 2 
experimental days over the course of 8-11 weeks. Experimental Day 1 will 
occur prior to the 8 weeks hot tub sessions, and day 2 will occur immediately 






5. During the screening session, we will schedule your initial experimental days 
(2 sessions), the start of your hot tub sessions, and tentatively schedule all 
other sessions. We will give you a hard copy of your schedule to take home 
with you.  
 
Heating (hot tub) Sessions: 
1. You will report to the laboratory 4-5 times per week for 8 weeks, for a total of 
36 sessions. Each session will take approximately 2-2.5 hours. You will be 
asked to bring a swimsuit to wear during the session. If you do not have one, 
we will provide one for you to use for the duration of the 8 weeks. No other 
subjects will use the same swimsuit.  
2. You will be asked to provide a urine sample so that we can ensure you are 
properly hydrated before undergoing heat stress. If you are dehydrated, we 
will give you 5mL/kg body weight (about half a normal sized 20oz bottle of 
Gatorade®) of fluids to drink prior to getting in the hot tub.  
3. Your nude body weight will be measured by a member of the same sex prior to 
getting in the hot tub. You will stand behind a privacy screen while this 
measurement is taken. Your nude body weight will also be measured following 
heat stress. This will be done so that we can quantify the volume of sweat you 
lose while in the tub.  
4. You will be instrumented with a Polar® heart rate monitor chest strap so that 
we can continuously monitor your heart rate throughout the procedure.  
5. We will give you a rectal probe labeled with your subject number. It is made of 
a thin rubber (flexible) material that is inserted 10 cm (approximately 4 
inches) past the anal sphincter. The probe will remain in place throughout the 
entire study session (up to 2.5 hours). The probe has a “tail” that will be 
connected to an external apparatus. The procedure may be a little 
uncomfortable at first (during insertion) but it should not be painful at any 
time. You will be instructed how to self-insert the rectal probe, as well as how 






sex will help you. Once in place, you may not even feel the probe at all. This 
technique is widely used and it’s considered the “gold standard” procedure for 
measuring body (“core”) temperature. 
6. On the very first and very last heating session (and possibly during one session at 
about 4wks), we will place 1 small flexible needle (these are called “intravenous 
catheters”, and are smaller than the lead of a pencil) into a vein near your 
elbow. The skin will be cleaned before this procedure. This catheter will remain 
in your vein throughout the heating session. We will take about 40ml of blood, 
about 2.7 tablespoons, prior to getting into the bathtub, and another 25ml of 
blood at the end of the heating period so that we can measure various factors in 
your blood that are affected by the heat exposure. We will remove the catheter 
after the second blood draw and place a sterile bandage over the site. The vials 
in which we collect the blood will be coded such that the investigators can 
determine all samples came from the same subject and the time the sample was 
taken. No one will be able to determine your identity from the sample.    
7. You will then be transferred to a bathtub that will be filled with water at 40°C 
(104.0°F). The tub is hooked up to a water pump and heater such that water 
can be circulated and maintained at a desired temperature. You will lay down 
in the bath tub such that the water level comes up to the level of your collar 
bone (to the top of your shoulders). You will lay down in this position until 
your core temperature has reached 38.5°C (101.3°F). This takes approximately 
25-35 minutes. At this point, you will sit up such that the water level reaches 
the middle of your chest (with your shoulders and arms out of the water). You 
will remain sitting up for another 60 minutes, or until the total time in the hot 
tub reaches 90 minutes, whichever comes first.  
8. We will continuously check in with you throughout the hot tub session. You 
will be instructed to inform an investigator if you feel any of the following 
symptoms: light-headedness, dizziness, nausea, headache, or if you feel 
unbearably warm. If you feel these symptoms, we will have you sit up if you 






if you were previously sitting up. If your body temperature gets too high (above 
39.5°C, 103°F), we will have you get out of the bath, even if you feel fine.  
9. You will be allowed to drink fluids while in the hot tub. 
10. At the end of the heating period, you will get out of the hot tub and sit in a 
recovery chair. We will continue to monitor your body temperature until your 
core temperature begins to return back to normal. If your body temperature 
remains high for too long, or if you feel too hot, dizzy, or nauseous, we will cool 
you down more quickly with cold packs. We will provide you with a towel to 
dry off during this time.  
11. Once you feel fine, you will remove the rectal probe, clean it, and place it in a 
location allocated to you.  
12. If you lost >1% of your body weight while in the hot tub due to sweating, we 
will ask you to drink fluids prior to leaving the lab in an amount necessary to 
return you to no more than a 1% loss of body weight.    
13. We will also offer you a light snack before leaving the lab.  
 
Experimental Days 1 and 2 (Skin Studies):  
1. You will arrive at Dr. Minson’s laboratory in Esslinger Hall at the University of 
Oregon to participate in the experimental protocol. The testing will take 
approximately 4-5 hours. The day before the study, we will contact you (either 
by phone or email depending on your preference) to remind you to refrain 
from all over-the-counter medications, including vitamins and supplements, for 
24 hours, alcohol and caffeine for 12 hours, food for 4 hours, and heavy 
exercise for 24 hours. Additionally, you will be asked to wear a short-sleeved 
shirt. 
2. Upon arrival at the laboratory, your height and weight and resting blood 
pressure will be measured. Female subjects will be asked to take a urine 
pregnancy test. You cannot participate in the study if the pregnancy test is 






6. We will place 3 small tubes (these are called “microdialysis fibers”, and are 
about the size of sewing thread) in the skin of your forearm. A small needle will 
be placed just under the surface of your skin and will exit back out about 1½ 
inches from where it entered your skin.  The small tubes will be placed inside 
the needle, and the needle will be withdrawn, leaving the small tubes under 
your skin.  These will remain in your skin throughout the rest of the study.  
7. We need to wait about 1-2 hours after the small tubes are placed in your skin to 
let the insertion trauma (redness of your skin around the small tubes) to go 
away.  During this time, a small probe (laser-Doppler probe) will be placed 
over each area of skin where the small tubes are so that we can measure skin 
blood flow over the small tube.   
8. During the study, we may periodically inflate a small cuff that is placed on your 
middle finger of one of your hands to measure your blood pressure (Portapres 
device).  We will only inflate this cuff for about 10 minutes at a time.  If the cuff 
becomes uncomfortable, let the investigator know and they will turn it off for a 
few minutes. 
9. Blood pressure will also be measured periodically throughout the study using 
an inflation cuff on your upper arm.  
10. During the protocol we will put some very small doses of drugs through the 
small tubes in your skin.  These drugs will cause the vessels of your skin to 
either widen or become narrow.  You should not feel anything when the drugs 
are going into your skin.  However, it is possible you may feel a slight tingling in 
the skin where the probe is. You will receive the following drugs:  
a. L-NNA:  this stops nitric oxide from being produced and causes the skin 
vessels to narrow 
b. Tempol: This is a substance that may cause your blood vessels to open.  
c. Sodium nitroprusside:  this is a substance that is used to lower blood 
pressure in patients and causes the skin vessels to open 
11. We will heat a small area of your skin with a small heater up to 43.5° Celsius 






temperature where heating becomes painful (about 113 degrees Fahrenheit) 
and well below the temperature that may burn your skin (about 117 degrees 
Fahrenheit).  If you think the heater is becoming painful, you need to tell the 
investigator and the temperature will be lowered. 
12. After the study, we will remove the small tubes in your skin and a bandage will be 
placed over the area of skin where the tubes were placed. 
13. Although you will not be allowed food or beverages during the study, you will be 
given a light snack and fluids to drink before you leave. 
 
 
Optional Follow-Up Testing:  
If you are interested and if you continue to qualify, you may be asked by the 
investigators to return to the laboratory after you have completed the 8 weeks of 
hot water immersion. This is so that we can assess how long any changes in your 
cardiovascular health last. Follow-up testing would take place 2, 4, 6, and/ 8 weeks 
after your last hot tub session. If you are interested in participating in follow-up 
testing, you will be asked to give consent and will sign an additional consent form 
closer to the end of your 8 weeks of hot water immersion. Importantly, if you are 
not interested in participating in follow-up testing, it does not affect your 
participation in the primary study, the 8 weeks of hot water immersion. Also 
please note that all time frames and compensation amounts in this section of the 
consent form only include the initial 8 weeks of hot water immersion.  
If you are interested in being asked later on about participating in follow-up  
testing, please initial here: _______. You can still change your mind at any time.
   
How long will I be in the study? 
You will be in the study for 8-11 weeks. You will participate in one screening 
session (about 60 min), seven experimental days (a total of up to 25 hours), and 36 
heating sessions (up to 2 hours per session).  






1. Heat exposure: There are some risks associated with heat exposure, including: 
fatigue, light-headedness, muscle cramps, dehydration, and neurological 
detriments (i.e. heat stroke). However, these symptoms do not typically occur 
until core temperature rises above 40°C. Your core temperature will be 
constantly recorded (rectal probe), and you will be removed from the hot bath 
immediately if either core temperature reaches 39.5°C or you experience any 
symptoms of heat-related illness. You will be instructed to notify the 
investigators immediately if you experience any of these symptoms. All 
symptoms subside upon lowering core temperature. Ice packs will be on hand 
for rapid cooling if necessary. Additionally, heat exposure may have 
detrimental effects on a developing fetus in females and` on sperm counts in 
males. Thus, subjects who are pregnant, trying to conceive, and/or undergoing 
treatment to increase sperm counts will be excluded from the study.   
2. Rectal temperature probes: The use of rectal probes to measure core body 
temperature, even during exercise, carries minimal risk. The primary risk is of 
damage to the lining of the rectum; however, this risk is very slight as we use a 
flexible probe that is designed for this purpose.  There is also the risk of 
infection, either by you not washing your hands properly or exposure to a 
poorly cleaned probe. The probe has been sterilized before use, and we will 
instruct you on how to properly clean the probe after each time you use it. The 
risk of infection is similar to that of having a bowel movement, and is 
considered minimal (similar to daily experience).  There is also the risk of 
embarrassment. The approach is typically well tolerated by subjects, and the 
investigative team is professional in regard to how they treat you. 
3. Venous blood draws and catheters: There may be some discomfort during the 
blood draw. Once the catheter is in place, or once the needle is removed, the 
pain should subside. After the blood draw, the needle will be withdrawn and a 
sterile dressing will be applied. Any swelling or redness after the study should 
subside by a few hours after completion of the study. Although the needles are 






in your skin. You will be instructed how to keep the area clean for a day or two 
following the experimental day. The most common complications of inserting a 
small needle into a vein is a small bruise and pain at the site of the needle 
location which may last several days after removal of the needle. A small 
amount of bleeding may occur directly after removal of the catheter. 
Application of pressure and a gauze dressing will alleviate the bleeding. The 
maximum amount of blood we will draw across the entire study is 270ml, or 
about 18 tablespoons, which is well below the volume drawn in a standard 
blood donation (~450ml). Even so, we will exclude you from the study if you 
have donated blood within the last two months. 
4. Skin microdialysis: There may be some discomfort during the insertion of the 
small fibers in your skin.  Once the needle is in place, the pain should subside.  
There is also a risk of syncope (fainting) during needle placement. You will be 
sitting in a reclining chair during the study, which reduces this risk, and you 
will be asked to inform the investigator if you feel light-headed, nauseous, 
dizzy, etc. during needle placement. If you do experience any of these 
symptoms, we will discontinue placing the needles and ensure the symptoms 
subside. Infusions through the fibers should not be painful, and there should 
only be minor swelling at the site.  At the end of the study, the fibers will be 
withdrawn and a sterile dressing will be applied.  Any swelling or redness after 
the study should be gone a few hours after completion of the study.  Although 
the small tubes are sterile, there is a slight risk of infection and/or allergic 
reaction at the sites where the small tubes were placed in your skin.  You will 
be instructed how to keep the area clean for a day or two following the study. If 
you see any signs of infection (redness, swelling, and/or pain around the sites) 
or experience some other abnormal reaction at the insertion site following the 
study, please contact us immediately. We will show you photos of what normal 
and abnormal healing looks like at the sites. There is a possibility the fibers 
may break while in your skin or while they are being removed. We remove the 






break. However, there is still a slight risk a small part of the fiber could remain 
in your skin. If this occurs, the piece should be able to work its way out of the 
skin within a few days (similar to a splinter), and we will follow-up with you to 
ensure this has happened. If the piece does not work its way out, or if a site 
seems infected, we will evaluate the site(s) and, if necessary, recommend you 
seek medical treatment with a healthcare provider. 
5. Microdialysis drugs: We will be infusing very small doses of each drug and only 
into a very small area of your skin.  You will not have any systemic (whole 
body) effects of these drugs, and they will not alter your blood pressure in the 
small doses given in this study.  However, as with any infusions or medications, 
there is the possibility that you are allergic to the drug and may have an allergic 
reaction to the drug including changes in blood pressure and difficulty 
breathing. In the case of an adverse event, the study will be discontinued. 
Investigators are trained in Advanced Cardiac Life Support and anaphylaxis. 
6. Local Skin Heating:  The local skin heaters may cause some minor skin 
discomfort.  The goal is to warm the area of skin to a temperature that has been 
determined to be below the threshold for pain.  If the local heating becomes 
painful, you should tell the investigator and the temperature of the local heater 
will be lowered.  There is a slight risk of burning the skin at this site, so it is 
important that you tell the investigators of any pain you are feeling.  The 
heating device may be removed at any time if you experience any discomfort. 
7. Laser-Doppler Probes:  These probes send a small light into your skin.  You will 
not feel anything except the probe touching your skin. There are no major risks 
associated with this procedure. 
8. Emergencies:  In the event of an emergency, you will be transported by 
ambulance to a local emergency facility. 
May I participate if I am pregnant or breast-feeding? 
No. There is not enough medical information to know what the risks might be to a 






feeding mothers are not able to take part in this study. Women who can still become 
pregnant must have a negative pregnancy test no more than 24 hours before taking part 
in each experimental day. If the pregnancy test is positive (meaning that you are 
pregnant), you will no longer be able to take part in the study. 
Are there benefits to taking part in this study? 
This study will likely not make your health better. This study is being conducted to 
learn about the effects of chronic heat exposure on cardiovascular health. It is possible 
the information gathered in this study could be used to better treat patients with elevated 
cardiovascular risk in the future.  
What other choices do I have if I don’t take part in this study? 
This study is only being done to gather information.  You may choose not to take part in 
this study. 
What are the costs of tests and procedures? 
You will not need to pay for any tests or procedures that are done just for this 
research study. You will receive compensation for completed each session in the 
study as follows: initial screening session, $10; Experimental Days 1-5, $30 each; 
Experimental Day 6, $50; Experimental Days 7, $40 each; and $10 per heating 
session completed. If you complete all parts of the study, you will receive $630. 
This money is for the inconvenience and time you spent in this study, and works 
out to be approximately $10 per hour of participation in experimental days and 
$10 per heating session.  If you start the study but stop before the study has ended, 
you will get part of this money. The partial amount will be calculated based on 
which study sessions you completed. You will receive compensation in the form of 
a check at the end of the study, or if you prefer, approximately every 2 weeks into 
the study. If you choose to receive compensation every 2 weeks, you will receive 
an amount corresponding to which study sessions you completed in each two-
week time interval. There will be no difference in the total compensation you will 







Please note, compensation from participation in Human Subjects Research 
studies may be considered taxable income.  Compensation amounts are tracked 
across all studies in which you participate. If compensation totals $600 or more in 
a calendar year, the University is required to report the income to the 
IRS.  University departments are required to track participant compensation and 
may contact you to complete a W9 form for tax reporting purposes.   Because of 
this, your name will be associated with participation in a research 
study. Department and university administrators will have access to this 
information, but will not have access to research data. 
Who can answer my questions? 
You may talk to Dr. Christopher Minson or his student, Vienna Brunt, M.S. at any 
time about any question you have on this study.  You may contact Dr. Minson by 
calling (541) 346-4105, (541) 346-4311 or on his cell phone (541) 953-2231, and 
Vienna Brunt at (541) 346-4507 or on her cell phone at (541) 968-2635. 
What are my rights if I take part in this study? 
Taking part in this research study is your decision.  You do not have to take part in 
this study, but if you do, you can stop at any time. Your decision whether or not to 
participate will not affect your relationship with The University of Oregon. 
You do not waive any liability rights for personal injury by signing this 
form.  All forms of medical diagnosis and treatment whether routine or 
experimental, involve some risk of injury.  In spite of all precautions, you might 
develop medical complications from participating in this study. 
The investigators may stop you from taking part in this study at any time if 
it is in your best interest, if you do not follow the study rules, or if the study is 
stopped.  You will be told of important new findings or any changes in the study or 
procedures that may happen. 
If you experience harm because of the project, you can ask the State of 
Oregon to pay you. A law called the Oregon Tort Claims Act limits the amount of 
money you can receive from the State of Oregon if you are harmed. If you have 






are their addresses and phone numbers: 
 General Counsel  Research Compliance Services 
 Office of the President University of Oregon 
 University of Oregon  Eugene, OR  97403 
 Eugene, OR 97403  (541) 346-2510 
 (541) 346-3082 
What about confidentiality? 
Any information that is obtained in connection with this study and that can be 
identified with you will remain confidential and will be disclosed only with your 
permission. Subject identities will be kept confidential by assigning you a “subject 
identification number”.  The names associated with each subject identification 
number will be stored on a secure computer with double password protection in 
Dr. Minson’s office and only one list with names and identification numbers will 
exist.  This list will be destroyed after all data has been collected and analyzed and 
for a period of one year after the results from the study have been published. Only 
coded specimens and data will exist thereafter. 
Your blood will be analyzed for such things as heat shock proteins, 
hormone concentrations, and cytokines (factors released by cells that affect other 
cells). Your muscle tissue will be analyzed for changes in DNA (not genetic 
testing), RNA, cell signaling, and changes in cell structure. The researchers may 
store the information gathered during this study indefinitely.  
I have had an opportunity to have my questions answered.  I have been given 
a copy of this form.  I agree to take part in this study.   
If you have questions regarding your rights as a research subject, contact Research 
Compliance Services, 5219 University of Oregon, Eugene, OR 97403, 541/346-
2510. 
Your signature indicates that you have read and understand the 
information provided above, that you willingly agree to participate, that you may 






that you will receive a copy of this form, and that you are not waiving any legal 
claims, rights or remedies. 
                                                                                                                       
(Date)                      (Signature of Participant)                                 
                                                                                                                      
                                (Printed Name of Participant)                                  
                                                                                                             




Group 2: Able-bodied thermoneutral water immersion 
TITLE: “Chronic heat exposure and cardiovascular health”   
INVESTIGATORS: Vienna E Brunt, M.S., Dr. Christopher T Minson, and colleagues 
APPROVED BY INSTITUTIONAL REVIEW BOARD:  February 5, 2014 
This is an important form.  Please read it carefully.  It tells you what you need to know 
about this study.  If you agree to take part in this research study, you need to sign this 
form.  Your signature means that you have been told about the study and what the risks 
are.  Your signature on this form also means that you want to take part in this study. 
Why is this study being done? 
Cardiovascular disease is the number one cause of death in the United States. 
Exercise is a potent means of improving cardiovascular health, but not all patient 
populations are able to exercise effectively. There is high demand for novel 
therapies to better manage cardiovascular risk in these patients. Heat exposure 
can have many beneficial effects on the cardiovascular system. As such, long-term 
heat exposure (i.e. sitting in a hot tub 4-5x per week) may provide an alternative 
means to exercise for improving cardiovascular health. This project will assess the 
benefits of long-term heat exposure on the health of the vasculature and on the 






of cardiovascular diseases affect the arteries. We will measure various biomarkers 
of vascular health before and after 8 weeks of heat exposure in able-bodied 
individuals and patients with spinal cord injury. SCI patients are a population with 
elevated cardiovascular risk who have limited exercise capabilities, and who may 
benefit greatly from chronic heat exposure. 
We will address the following questions in this study:   
• How does 8 weeks of passive heat exposure affect cardiovascular health, as 
measured by various biomarkers of cardiovascular function? 
• How does 8 weeks of passive heat exposure affect levels of factors circulating 
in the blood and located within muscle tissue that are important for 
cardiovascular health? 
• Do effects differ between healthy able-bodied individuals and spinal cord 
injury patients?  
 
 
What will happen in the study? 
1. If you meet all the initial subject criteria (based on initial phone and/or email 
conversations) and are interested in participating in the study, we will 
schedule an appointment with you to meet with one of the investigators of the 
study to discuss the project, to see the laboratory, and to read this form. 
Additionally, you will fill out a health history form so that we can ensure you 
are healthy enough to participate in the study. This visit should last about 60 
minutes.  
2. We will assign you to a subject group. To do this, we will match you to a spinal 
cord injury patient who is currently enrolled in the study based on your age, 
sex, and approximate fitness level. You will be assigned to the same group 
(heating or thermoneutral/control) as that subject. You will be informed of 
what group you are in prior to reading this form. If you are reading this form, 






3. Throughout the study, you will report to the laboratory 4-5 times per week for 
thermoneutral water immersion sessions. You will participate in 2 
experimental days over the course of 8-11 weeks. Experimental Day 1 will 
occur prior to the 8 weeks thermoneutral water immersion, and Day 2 will 
occur immediately following the 8 weeks of thermoneutral water immersion.  
4. During the screening session, we will schedule your initial experimental days 
(3 sessions), the start of your thermoneutral water immersion sessions, and 
tentatively schedule all other sessions. We will give you a hard copy of your 
schedule to take home with you.  
 
Thermoneutral Water Immersion Sessions: 
1. You will report to the laboratory 4-5 times per week for 8 weeks, for a total of 
36 sessions. Each session will take approximately 2-2.5 hours. You will be 
asked to bring a swimsuit to wear during the session. If you do not have one, 
we will provide one for you to use for the duration of the 8 weeks. No other 
subjects will use the same swimsuit.  
2. You may be asked to provide a urine sample so that we can ensure you are 
properly hydrated. If you are dehydrated, we will give you 5mL/kg body 
weight (about half a normal sized 20oz bottle of Gatorade®) of fluids to drink 
prior to getting in the tub. You will be able to drink fluids throughout the water 
immersion period.  
3. You will be instrumented with a Polar® heart rate monitor chest strap so that 
we can continuously monitor your heart rate throughout the procedure.  
4. We will give you a rectal probe labeled with your subject number. It is made of 
a thin rubber (flexible) material that is inserted 10 cm (approximately 4 
inches) past the anal sphincter. The probe will remain in place throughout the 
entire study session (up to 2.5 hours). The probe has a “tail” that will be 
connected to an external apparatus. The procedure may be a little 
uncomfortable at first (during insertion) but it should not be painful at 






how to remove it and clean it. If you needed assistance, a lab researcher of the 
same sex will help you. Once in place, you may not even feel the probe at all. 
This technique is widely used and it’s considered the “gold standard” 
procedure for measuring body (“core”) temperature. 
5. On the very first and very last heating session (and possibly during one sesson at 
about 4wks), we will place 1 small flexible needle (these are called “intravenous 
catheters”, and are smaller than the lead of a pencil) into a vein near your 
elbow. The skin will be cleaned before this procedure. This catheter will remain 
in your vein throughout the water immersion session. We will take about 40ml 
of blood, about 2.7 tablespoons, prior to getting into the bathtub, and another 
25ml of blood at the end of the heating period so that we can measure various 
factors in your blood that may be affected by heat exposure. We will remove 
the catheter after the second blood draw and place a sterile bandage over the 
site. The vials in which we collect the blood will be coded such that the 
investigators can determine all samples came from the same subject and the 
time the sample was taken. No one will be able to determine your identity from 
the sample.    
6. You will then be transferred to a hot tub. The tub will be filled with water at 
36°C (96.8°F). The tub is hooked up to a water pump and heater such that 
water can be circulated and maintained at a desired temperature. You will lay 
down in the bath tub such that the water level comes up to the level of your 
collar bone (to the top of your shoulders). You will lay down in this position for 
30 minutes. At this point, you will sit up such that the water level reaches the 
middle of your chest (with your shoulders and arms out of the water). You will 
remain sitting up for another 60 minutes.  
7. At the end of the water immersion period, you will get out of the tub and sit in a 
recovery chair. We will give you cool fluids to drink and a towel to dry off, and 
will offer you a light snack.  
8. We will instruct you on how to remove the rectal probe, clean it, and place it in 







Experimental Days 1 and 7 (Skin Studies):  
1. You will arrive at Dr. Minson’s laboratory in Esslinger Hall at the University of 
Oregon to participate in the experimental protocol. The testing will take 
approximately 4-5 hours. The day before the study, we will contact you (either 
by phone or email depending on your preference) to remind you to refrain 
from all over-the-counter medications, including vitamins and supplements, for 
24 hours, alcohol and caffeine for 12 hours, food for 4 hours, and heavy 
exercise for 24 hours. Additionally, you will be asked to wear a short-sleeved 
shirt. 
2. Upon arrival at the laboratory, your height and weight and resting blood 
pressure will be measured. Female subjects will be asked to take a urine 
pregnancy test. You cannot participate in the study if the pregnancy test is 
positive, as the study procedures could be harmful to an unborn child. 
3. We will place 3 small tubes (these are called “microdialysis fibers”, and are 
about the size of sewing thread) in the skin of your forearm. A small needle will 
be placed just under the surface of your skin and will exit back out about 1½ 
inches from where it entered your skin.  The small tubes will be placed inside 
the needle, and the needle will be withdrawn, leaving the small tubes under 
your skin.  These will remain in your skin throughout the rest of the study.  
4. We need to wait about 1-2 hours after the small tubes are placed in your skin to 
let the insertion trauma (redness of your skin around the small tubes) to go 
away.  During this time, a small probe (laser-Doppler probe) will be placed 
over each area of skin where the small tubes are so that we can measure skin 
blood flow over the small tube.   
5. During the study, we may periodically inflate a small cuff that is placed on your 
middle finger of one of your hands to measure your blood pressure (Portapres 
device).  We will only inflate this cuff for about 10 minutes at a time.  If the cuff 







6. Blood pressure will also be measured periodically throughout the study using 
an inflation cuff on your upper arm.  
7. During the protocol we will put some very small doses of drugs through the 
small tubes in your skin.  These drugs will cause the vessels of your skin to 
either widen or become narrow.  You should not feel anything when the drugs 
are going into your skin.  However, it is possible you may feel a slight tingling in 
the skin where the probe is. You will receive the following drugs:  
a. L-NNA:  this stops nitric oxide from being produced and causes the skin 
vessels to narrow 
b. Tempol: This is a substance that may cause your blood vessels to open.  
c. Sodium nitroprusside:  this is a substance that is used to lower blood 
pressure in patients and causes the skin vessels to open 
8. We will heat a small area of your skin with a small heater up to 43.5° Celsius 
(110 degrees Fahrenheit) to open the vessels in your skin.  This is below the 
temperature where heating becomes painful (about 113 degrees Fahrenheit) 
and well below the temperature that may burn your skin (about 117 degrees 
Fahrenheit).  If you think the heater is becoming painful, you need to tell the 
investigator and the temperature will be lowered. 
9. After the study, we will remove the small tubes in your skin and a bandage will 
be placed over the area of skin where the tubes were placed. 
 
Although you will not be allowed food or beverages during the study, you will be given 
a light snack and fluids to drink before you leave. 
 
How long will I be in the study? 
You will be in the study for 8-11 weeks. You will participate in one screening 
session (about 60 min), seven experimental days (a total of up to 25 hours), and 36 
water immersion sessions (up to 2 hours each).  
 






1. Rectal temperature probes: The use of rectal probes to measure core body 
temperature, even during exercise, carries minimal risk. The primary risk is of 
damage to the lining of the rectum; however, this risk is very slight as we use a 
flexible probe that is designed for this purpose.  There is also the risk of 
infection, either by you not washing your hands properly or exposure to a 
poorly cleaned probe. The probe has been sterilized before use, and we will 
instruct you on how to properly clean the probe after each time you use it. The 
risk of infection is similar to that of having a bowel movement, and is 
considered minimal (similar to daily experience).  There is also the risk of 
embarrassment. The approach is typically well tolerated by subjects, and the 
investigative team is professional in regard to how they will treat you. 
2. Venous blood draws and catheters: There may be some discomfort during the 
blood draw. Once the catheter is in place, or once the needle is removed, the 
pain should subside. After the blood draw, the needle will be withdrawn and a 
sterile dressing will be applied. Any swelling or redness after the study should 
subside by a few hours after completion of the study. Although the needles are 
sterile, there is a slight risk of infection at the site where the needle was placed 
in your skin. You will be instructed how to keep the area clean for a day or two 
following the experimental day. The most common complications of inserting a 
small needle into a vein is a small bruise and pain at the site of the needle 
location which may last several days after removal of the needle. A small 
amount of bleeding may occur directly after removal of the catheter. 
Application of pressure and a gauze dressing will alleviate the bleeding. The 
maximum amount of blood we will draw across the entire study is 270ml, or 
about 18 tablespoons, which is well below the volume drawn in a standard 
blood donation (~450ml). Even so, we will exclude you from the study if you 
have donated blood within the last two months. 
3. Skin microdialysis: There may be some discomfort during the insertion of the 
small fibers in your skin.  Once the needle is in place, the pain should subside.  






sitting in a reclining chair during the study, which reduces this risk, and you 
will be asked to inform the investigator if you feel light-headed, nauseous, 
dizzy, etc. during needle placement. If you do experience any of these 
symptoms, we will discontinue placing the needles and ensure the symptoms 
subside. Infusions through the fibers should not be painful, and there should 
only be minor swelling at the site.  At the end of the study, the fibers will be 
withdrawn and a sterile dressing will be applied.  Any swelling or redness after 
the study should be gone a few hours after completion of the study.  Although 
the small tubes are sterile, there is a slight risk of infection and/or allergic 
reaction at the sites where the small tubes were placed in your skin.  You will 
be instructed how to keep the area clean for a day or two following the study. If 
you see any signs of infection (redness, swelling, and/or pain around the sites) 
or experience some other abnormal reaction at the insertion site following the 
study, please contact us immediately. We will show you photos of what normal 
and abnormal healing looks like at the sites. There is a possibility the fibers 
may break while in your skin or while they are being removed. We remove the 
fibers in a way such that we can still remove the entire fiber, even if it does 
break. However, there is still a slight risk a small part of the fiber could remain 
in your skin. If this occurs, the piece should be able to work its way out of the 
skin within a few days (similar to a splinter), and we will follow-up with you to 
ensure this has happened. If the piece does not work its way out, or if a site 
seems infected, we will evaluate the site(s) and, if necessary, recommend you 
seek medical treatment with a healthcare provider. 
4. Microdialysis drugs: We will be infusing very small doses of each drug and only 
into a very small area of your skin.  You will not have any systemic (whole 
body) effects of these drugs, and they will not alter your blood pressure in the 
small doses given in this study.  However, as with any infusions or medications, 
there is the possibility that you are allergic to the drug and may have an allergic 
reaction to the drug including changes in blood pressure and difficulty 






Investigators are trained in Advanced Cardiac Life Support and anaphylaxis. 
5. Local Skin Heating:  The local skin heaters may cause some minor skin 
discomfort.  The goal is to warm the area of skin to a temperature that has been 
determined to be below the threshold for pain.  If the local heating becomes 
painful, you should tell the investigator and the temperature of the local heater 
will be lowered.  There is a slight risk of burning the skin at this site, so it is 
important that you tell the investigators of any pain you are feeling.  The 
heating device may be removed at any time if you experience any discomfort. 
6. Laser-Doppler Probes:  These probes send a small light into your skin.  You will 
not feel anything except the probe touching your skin. There are no major risks 
associated with this procedure. 
7. Emergencies:  In the event of an emergency, you will be transported by 
ambulance to a local emergency facility. 
May I participate if I am pregnant or breast-feeding? 
No. There is not enough medical information to know what the risks might be to a 
breast-fed infant or to an unborn child in a woman who takes part in this study.  Breast-
feeding mothers are not able to take part in this study. Women who can still become 
pregnant must have a negative pregnancy test no more than 24 hours before taking part 
in each experimental day. If the pregnancy test is positive (meaning that you are 
pregnant), you will no longer be able to take part in the study. 
Are there benefits to taking part in this study? 
This study will likely not make your health better. This study is being conducted to 
learn about the effects of chronic heat exposure on cardiovascular health. It is possible 
the information gathered in this study could be used to better treat patients with elevated 
cardiovascular risk in the future.  
What other choices do I have if I don’t take part in this study? 
This study is only being done to gather information.  You may choose not to take part in 
this study. 






You will not need to pay for any tests or procedures that are done just for this 
research study. You will receive compensation for completed each session in the 
study as follows: initial screening session, $10; Experimental Days 1-5, $30 each; 
Experimental Day 6, $50; Experimental Days 7, $40 each; and $10 per heating 
session completed. If you complete all parts of the study, you will receive $630. 
This money is for the inconvenience and time you spent in this study, and works 
out to be approximately $10 per hour of participation in experimental days and 
$10 per heating session.  If you start the study but stop before the study has ended, 
you will get part of this money. The partial amount will be calculated based on 
which study sessions you completed. You will receive compensation in the form of 
a check at the end of the study, or if you prefer, approximately every 2 weeks into 
the study. If you choose to receive compensation every 2 weeks, you will receive 
an amount corresponding to which study sessions you completed in each two-
week time interval. There will be no difference in the total compensation you will 
receive if you chose to receive compensation at the end of the study versus every 2 
weeks. 
Please note, compensation from participation in Human Subjects Research 
studies may be considered taxable income.  Compensation amounts are tracked 
across all studies in which you participate. If compensation totals $600 or more in 
a calendar year, the University is required to report the income to the 
IRS.  University departments are required to track participant compensation and 
may contact you to complete a W9 form for tax reporting purposes.   Because of 
this, your name will be associated with participation in a research 
study. Department and university administrators will have access to this 
information, but will not have access to research data. 
Who can answer my questions? 
You may talk to Dr. Christopher Minson or his student, Vienna Brunt, M.S. at any 
time about any question you have on this study.  You may contact Dr. Minson by 
calling (541) 346-4105, (541) 346-4311 or on his cell phone (541) 953-2231, and 






What are my rights if I take part in this study? 
Taking part in this research study is your decision.  You do not have to take part in 
this study, but if you do, you can stop at any time. Your decision whether or not to 
participate will not affect your relationship with The University of Oregon. 
You do not waive any liability rights for personal injury by signing this 
form.  All forms of medical diagnosis and treatment whether routine or 
experimental, involve some risk of injury.  In spite of all precautions, you might 
develop medical complications from participating in this study. 
The investigators may stop you from taking part in this study at any time if 
it is in your best interest, if you do not follow the study rules, or if the study is 
stopped.  You will be told of important new findings or any changes in the study or 
procedures that may happen. 
 If you experience harm because of the project, you can ask the State of 
Oregon to pay you. A law called the Oregon Tort Claims Act limits the amount of 
money you can receive from the State of Oregon if you are harmed. If you have 
been harmed, there are two University representatives you need to contact.  Here 
are their addresses and phone numbers: 
 General Counsel  Research Compliance Services 
 Office of the President University of Oregon 
 University of Oregon  Eugene, OR  97403 
 Eugene, OR 97403  (541) 346-2510 
 (541) 346-3082 
What about confidentiality? 
Any information that is obtained in connection with this study and that can be 
identified with you will remain confidential and will be disclosed only with your 
permission. Subject identities will be kept confidential by assigning you a “subject 
identification number”.  The names associated with each subject identification 
number will be stored on a secure computer with double password protection in 
Dr. Minson’s office and only one list with names and identification numbers will 






for a period of one year after the results from the study have been published. Only 
coded specimens and data will exist thereafter. 
Your blood will be analyzed for such things as heat shock proteins, 
hormone concentrations, and cytokines (factors released by cells that affect other 
cells). Your muscle tissue will be analyzed for changes in DNA (not genetic 
testing), RNA, cell signaling, and changes in cell structure. The researchers may 
store the information gathered during this study indefinitely.  
I have had an opportunity to have my questions answered.  I have been given 
a copy of this form.  I agree to take part in this study.   
If you have questions regarding your rights as a research subject, contact Research 
Compliance Services, 5219 University of Oregon, Eugene, OR 97403, 541/346-
2510. 
 
Your signature indicates that you have read and understand the information 
provided above, that you willingly agree to participate, that you may withdraw 
your consent at any time and discontinue participation without penalty, that you 
will receive a copy of this form, and that you are not waiving any legal claims, 
rights or remedies. 
                                                                                                                       
(Date)                      (Signature of Participant)                                 
                                                                                                                      
                                (Printed Name of Participant)                                  
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